# Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL

> **NCT03708003** · PHASE2 · TERMINATED · sponsor: **Swiss Cancer Institute** · enrollment: 30 (actual)

## Conditions studied

- Relapsed/Refractory Chronic Lymphocytic Leukemia
- Chronic Lymphocytic Leukemia
- Leukemia

## Interventions

- **DRUG:** Ibrutinib
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT03708003
- **Lead sponsor:** Swiss Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-03-11
- **Primary completion:** 2025-11-30
- **Final completion:** 2025-11-30
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** The board decision has been made to conclude the trial ahead of schedule. The primary endpoint has been successfully achieved and published, and funding was secured to support these three years of followup.
- **Last updated:** 2025-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03708003

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03708003, "Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03708003. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*